抗治疗性忧郁症市场：依药物类型、通路和地区划分

预计到2024年，抗治疗性忧郁症市场规模将达到19.1亿美元，2024年至2031年的复合年增长率为4.2%，预计到2031年将达到25.4亿美元。

图 1. 2024 年抗治疗性忧郁症市场占有率(%)，依地区划分

抗治疗性忧郁症(TRD) 是一种常见的精神疾病，患者对标准抗忧郁症反应不充分。大约 30% 至 50% 的重度忧郁症患者会出现 TRD。抗治疗性的确切原因仍不清楚，但据认为与生物和环境因素有关，例如遗传和神经系统变化。 TRD 患者会经历更严重的忧郁症症状，包括无价值感、极度悲伤、疲劳和对日常生活失去兴趣，这损害了他们的生活品质。如果不及时治疗，TRD 会增加残疾、功能障碍和自杀的风险。抗治疗性忧郁症市场包括旨在为抗忧郁症无反应的患者提供替代治疗选择的治疗方法方法。

市场动态：

全球抗治疗性忧郁症市场的成长是由全球 TRD 盛行率不断上升所推动的。据估计，超过 30% 的重度忧郁症患者在一线抗忧郁症治疗后并未获得缓解。这种反应迟钝会导致长期的痛苦和增加的经济负担。市场也受益于 TRD 诊断的改进和对可用治疗方案的认识的提高。然而，挑战包括新药的严格核准流程以及缺乏经核准的生物标记来确认抗治疗性。目前正在对潜在的生物学机制进行大量研究，以开发更有效的标靶治疗。此外，将心理社会干预措施和数位技术与药物治疗相结合的努力为市场相关人员提供了利润丰厚的机会。

本研究的主要特点

• 该报告对全球抗治疗性忧郁症市场进行了详细分析，包括以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，了解全球抗治疗性忧郁症市场的主要企业概况。
• 该报告的见解将帮助负责人和公司经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球抗治疗性忧郁症市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球抗治疗性忧郁症市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章 全球抗治疗性忧郁症市场：依药物类型划分，2019-2031 年（十亿美元）

• 抗忧郁症
• 非典型药物
• 其他的

第六章 全球抗治疗性忧郁症市场：依通路划分，2019-2031 年（十亿美元）

• 医院药房
• 零售药房
• 网路药房

第七章 全球抗治疗性忧郁症市场：按地区划分，2019-2031 年（十亿美元）

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章 竞争格局

• 公司简介
  • Eli Lilly and Company.
  • GlaxoSmithKline
  • Pfizer Inc.
  • Janssen Pharmaceuticals
  • AbbVie Inc.
  • AstraZeneca
  • H. Lundbeck A/S
  • Sandoz International GmbH
  • Par Pharmaceutical Companies Inc.
  • Otsuka Holdings Co., Ltd.
  • Wyeth
  • Scherinhg Plough CorporatioN
  • Vistagen therapeutics, Inc
  • Forest Laboratories
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceuticals
  • Lundbeck
  • Allergan
  • Supernus Pharmaceuticals
  • Sage Therapeutics
  • Neuralstem

第九章 分析师建议

• 命运之轮
• 分析师观点
• Coherent Opportunity Map

第10章 参考文献与调查方法

• 参考
• 调查方法

The Treatment Resistant Depression Market is estimated to be valued at USD 1.91 billion in 2024 and is expected to reach USD 2.54 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

Figure 1. Treatment Resistant Depression Market Share (%), By Region, 2024

Treatment resistant depression (TRD) is a widespread mental health condition wherein patients do not respond adequately to standard antidepressant medications. TRD affects approximately 30% to 50% of patients with major depressive disorder. The exact causes that lead to treatment resistance are still unclear but it is believed to involve biological factors like genetics and neurological changes as well as environmental contributors. Patients suffering from TRD experience more severe symptoms of depression like feelings of worthlessness, extreme sadness, fatigue and loss of interest in daily activities with an impaired quality of life. If left untreated, TRD can lead to increased disability, functional impairment and risk of suicide. The treatment resistant depression market comprises therapies aimed at providing alternative treatment options to patients who do not get the desired response from antidepressants.

Market Dynamics:

The global treatment resistant depression market growth is driven by the growing prevalence of TRD worldwide. It is estimated that over 30% of patients suffering from major depression do not achieve remission with first-line antidepressant therapy. This non-responsiveness leads to prolonged suffering and increased economic burden. The market also benefits from improved diagnosis of TRD and widespread awareness about available treatment options. However, factors such as stringent regulatory approval processes for new drugs and lack of approved biomarkers for confirming treatment resistance pose challenges. Significant research into the underlying biological mechanisms is underway to develop more effective targeted therapies. Moreover, initiatives to integrate psychosocial interventions and digital technologies with pharmacotherapy provide lucrative opportunities for market players.

Key features of the study:

• This report provides in-depth analysis of the global treatment resistant depression market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global treatment resistant depression market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Pfizer, GlaxoSmithKline, Merck, LivaNova, Sanofi, Medtronic, Boston Scientific, Brainsway and Nevro
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global treatment resistant depression market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Product Type
  • Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine Reuptake Inhibitors
  • Others
  • Atypical agents
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer Inc.
  • Janssen Pharmaceuticals
  • AbbVie Inc.
  • AstraZeneca
  • Lundbeck A/S
  • Sandoz International GmbH
  • Par Pharmaceutical Companies Inc.
  • Otsuka Holdings Co., Ltd.
  • Wyeth
  • Scherinhg Plough CorporatioN
  • Vistagen therapeutics, Inc
  • Forest Laboratories
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceuticals
  • Lundbeck
  • Allergan
  • Supernus Pharmaceuticals
  • Sage Therapeutics
  • Neuralstem

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Treatment Resistant Depression Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Treatment Resistant Depression Market, By Drug Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Antidepressants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Atypical agents
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Treatment Resistant Depression Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Treatment Resistant Depression Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

• Company Profiles
  • Eli Lilly and Company.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GlaxoSmithKline
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Janssen Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • H. Lundbeck A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sandoz International GmbH
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Par Pharmaceutical Companies Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Otsuka Holdings Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Wyeth
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Scherinhg Plough CorporatioN
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Vistagen therapeutics, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Forest Laboratories
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceuticals
  • Lundbeck
  • Allergan
  • Supernus Pharmaceuticals
  • Sage Therapeutics
  • Neuralstem

9. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact